Cardiocast

Forget what you learned about infective endocarditis

Publish date: March 7, 2019

 

This week in MDedge Cardiocast: Infective endocarditis isn’t what it used to be, there’s a new, lower goal for Americans’ dietary intake of sodium, a drug to treat multiple myeloma also raises heart failure risk, and Big Pharma says it can’t drop drug list prices alone.
Amazon Alexa
Apple Podcasts
Google Podcasts
TuneIn

Recommended Reading

SGLT-2 inhibitors promising for heart failure prevention, not treatment
MDedge Internal Medicine
HDL-P subfractions may be prognostic in heart failure
MDedge Internal Medicine
Subclinical hypothyroidism boosts immediate risk of heart failure
MDedge Internal Medicine
Atrial fib guidelines updated, SPRINT MIND published, and more
MDedge Internal Medicine
Immunotherapy’s cardiac effects require early monitoring, management
MDedge Internal Medicine
SGLT2 inhibitors morph into HF drugs
MDedge Internal Medicine
­­ADT harms likely limited to men with CV comorbidities
MDedge Internal Medicine
What comes first with SGLT2 inhibitors – diabetes or heart failure?
MDedge Internal Medicine
Heart failure outcomes are worse in select HIV-infected individuals
MDedge Internal Medicine
Infective endocarditis isn’t what it used to be
MDedge Internal Medicine